NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

If NWBO gets the results it is hoping for with Direct and L, they could buy Bristol Meyers Squibb with their pocket change. However, that being said, a partnering deal with Bristol Meyers is not out of the question. An immunological survey written in July 2013, Future Oncology 9(7) 2013 pages 977 to 990, suggested that even though the primary writer was working on a mAB therapy immunity therapy approach, he believed DC Vaccines are the primary therapy expectation and mAB therapy and PD1-PDL1 axis therapy will likely be adjuncts added to the DC treatment. The latter 2 have more safety concerns than dendritic cell therapy, but as Larry Smith also seems to suggest at the end of his article, these treatments may be synergistic as opposed to competition.